The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial

Hernandez, Cristina; Porta, Massimo; Bandello, Francesco; Grauslund, Jakob; Harding, Simon P.; Aldington, Stephen J.; Egan, Catherine; Frydkjaer-Olsen, Ulrik; Garcia-Arumi, Jose; Gibson, Jonathan; Lang, Gabriele E.; Lattanzio, Rosangela; Massin, Pascale; Midena, Edoardo; Ponsati, Berta; Ribeiro, Luisa; Scanlon, Peter; Cunha-Vaz, Jose; Simo, Rafael; Treatmen, European Consortium Early

Published in:
Journal of Clinical Medicine

DOI:
10.3390/jcm9041233

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version
The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial

Cristina Hernández, Massimo Porta, Francesco Bandello, Jakob Grauslund, Simon P. Harding, Stephen J. Aldington, Catherine Egan, Ulrik Frydkjaer-Olsen, José García-Arumí, Jonathan Gibson, Gabriele E. Lang, Rosangela Lattanzio, Pascale Massin, Edoardo Midena, Berta Ponsati, Luisa Ribeiro, Peter Scanlon, José Cunha-Vaz, and Rafael Simó for the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Abstract: The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA)) in the serum of 341 participants of the EUROCONDOR study at baseline, 24, and 48 weeks. Retinal neurodysfunction was assessed by measuring implicit time (IT) using multifocal electroretinography, and structural changes were examined by spectral domain–optical coherence tomography. The values of IT at baseline were directly correlated with baseline serum concentrations of CML ($r = 0.135$, $p = 0.013$). Furthermore, in the placebo group, increase in CML concentration throughout follow-up correlated with the IT ($r = 0.20$, $p = 0.03$). Baseline serum levels of CML also correlated with macular retinal thickness (RT) ($r = 0.231$, $p < 0.001$). Baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group ($r = 0.22$, $p = 0.016$). We provide evidence that CML may be a biomarker of both retinal neurodysfunction and
RT, whereas Lam-P1 was associated with RT only. Therefore, circulating levels of these molecules could provide a complementary tool for monitoring the early changes of diabetic retinopathy (DR).

**Keywords:** diabetic retinopathy; retinal neurodegeneration; serum biomarkers; laminin; carboxy methyl lysine; asymmetric dimethylarginine

1. Introduction

Diabetic retinopathy (DR) is the most frequent complication of diabetes and the main cause of visual impairment in working-age adults in developed countries [1,2]. Current treatments for DR, such as laser photocoagulation and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor (VEGF) agents, are applicable only at advanced stages of the disease, and are associated with significant adverse effects [3,4]. Fenofibrate and calcium dobesilate have been used as oral agents in the early stages of DR, but they are not included in current clinical guidelines [5]. Therefore, in the early stages of DR, the only therapeutic strategy that physicians can offer is a tight control of the main modifiable risk factors, such as glycemia and blood pressure. However, clinical studies in patients with diabetes reveal a substantial variation in the onset and severity of DR, thus indicating that genetic factors may influence the susceptibility of DR development and progression [6–8].

Circulating biomarkers could be useful for detecting early retinal disease before structural changes can be clearly seen using current imaging techniques. In addition, they may help to identify patients with diabetes that is more prone to progressive worsening, in whom intensified therapy could be prioritized, and to monitor the effectiveness of new drugs for DR before its advanced stages have developed. Research on biomarkers has been mainly based on the pathogenic mechanism involved in the development of DR, such as advanced glycation end products (AGEs), endothelial dysfunction, inflammation, and basement membrane and extracellular matrix turnover [9,10].

In recent years, the concept that neurodegeneration is an early event in the pathogenesis of DR has emerged, and pre-clinical evidence suggests that neuroprotection can be a therapeutic target [11,12]. In addition, several phenotypes based on retinal examination have been identified [13,14]. These findings have renewed the interest of circulating biomarkers as an important tool to complement the information provided by retinal assessments.

The EUROCONDOR study included a phase II–III randomized, controlled clinical trial aimed at evaluating the effects of topical neuroprotection in arresting or preventing early retinal neurodegeneration in DR [14,15]. The selected neuroprotective agents appear useful in preventing the worsening of preexisting retinal neurodysfunction [15]. This finding points to screening for retinal neurodysfunction as a critical issue, in order to identify a subset of patients in whom neuroprotective treatment might be of benefit. In this study, we wanted to test whether some circulating molecules can act as serum biomarkers in predicting either the worsening of retinal neurodysfunction, as assessed by multifocal electroretinography (mfERG), or structural changes, as assessed by a combination of spectral domain–optical coherence tomography (SD-OCT) and seven-field fundus photographs.

The selected molecules were based on three essential pathogenic factors involved in the very early stages of DR: basement membrane thickening [16,17], the accumulation of advanced glycation end-products (AGEs) [18,19], and oxidative stress [20,21].

As a biomarker of the increased thickening and turnover of the basement membrane that exists in diabetes, we selected laminin P1 (the largest pepsin resistant fragment of laminin), which is the main non-collagenous component of the basement membrane. Basement membranes of retinal vessels in diabetic rats contain increased amounts of laminin, as early as 8 weeks after the induction of diabetes, indicating increased expression of matrix components [22]. In addition, in a prospective study we found that circulating laminin-P1 was an early marker of the presence of DR, as well as a marker of its severity [23].
The selected molecule among AGEs was N-epsilon-carboxy methyl lysine (CML), which is found in the normal retina and with concentration greatly increased in the neuroglial and vascular components of the retina of patients with diabetes [24]. There is mounting evidence on the deleterious effects of AGEs in the early stages of DR [25–27], and their role in neurodegeneration has been comprehensively reviewed [28]. In addition, CML has been found to be elevated in the serum of patients with diabetes, and to an even greater extent in those with microvascular complications [9]. Furthermore, skin collagen CML levels, measured in human skin punch biopsy samples, predicted the progression of DR in a prospective study [29].

For testing oxidative stress—and more specifically, endothelium-derived oxidative stress—we have used serum asymmetric dimethylarginine (ADMA). Endothelial dysfunction and impaired ocular hemodynamics underlying DR development are associated with decreased nitric oxide (NO) synthase activity and NO bioavailability, thus resulting in vasoconstriction and increased reactive oxygen species (ROS) [30]. Serum asymmetric dimethylarginine (ADMA) is involved in the NO pathway, and serum levels of ADMA have been found to be elevated in patients with diabetes and DR [31,32]. Increased oxidative stress contributes to elevated ADMA. In turn, increased serum ADMA concentration is associated with increased vascular oxidative stress, as demonstrated by the upregulation of circulating markers of oxidative stress [30].

2. Experimental Section

EUROCONDOR [NCT01726075] was a 96 week, European multicenter, prospective, interventionial, phase II–III, randomized controlled clinical trial aimed at evaluating the effect of topical (eye drops) neuroprotective agents to arrest or prevent early retinal neurodegeneration in DR [14,15]. Briefly, 449 patients were recruited in 11 European centers and randomized 1:1:1 to topical treatment twice daily with a placebo, brimonidine tartrate 0.2%, or somatostatin 0.1%.

The inclusion criteria were type 2 diabetes with no, minimal, or mild DR (Early Treatment Diabetic Retinopathy Study (ETDRS) levels: 10, 20, or 35); known duration of diabetes at least 5 years; and age between 45 and 75 years. Relevant to this report, microvascular changes were assessed by using standard seven-field color fundus photography. Retinal neurodysfunction was assessed by mfERG, implicit time (IT) being the primary end-point. Structural changes were assessed by spectral domain–optical coherence tomography (SD-OCT). One eye per patient was included in the study. If both eyes met the inclusion criteria, one eye was chosen randomly.

The study was approved and funded by the European Commission Seventh Framework Program (grant agreement no. FP7–278040). At all centers, the study was conducted in accordance with the tenets of the Declaration of Helsinki, with approvals of the local scientific ethical committees; written informed consent was obtained from all patients.

2.1. Measurement of Biomarkers

Blood samples for potential biomarkers were taken at the screening visit (n = 449) and at weeks 24 and 48. The molecules were analyzed in patients that completed the 2 years of follow-up (n = 341). Serum circulating biomarkers were measured using the following enzyme-linked immunosorbent assay (ELISA) kits: Lam P1 fragment (cat. MBS9310966, MyBiosource, San Diego, CA, USA), CML (cat. STA-816, Cell Biolabs Inc, San Diego, CA, USA), and ADMA (cat. CEB301Ge, Cloud-Clone Corp., Wuhan, Hubei, China). Details of the ELISA kits are displayed in Table 1.
Table 1. Sensitivity and intra- and inter-assay coefficients of the measured circulating biomarkers.

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>Intra-Assay Coefficient</th>
<th>Inter-Assay Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML</td>
<td>2.25 ng/mL</td>
<td>&lt;10%</td>
<td>&lt;12%</td>
</tr>
<tr>
<td>Lam-P1</td>
<td>5.00 ng/mL</td>
<td>&lt;8%</td>
<td>&lt;12%</td>
</tr>
<tr>
<td>ADMA</td>
<td>4.34 ng/mL</td>
<td>&lt;8%</td>
<td>&lt;12%</td>
</tr>
</tbody>
</table>

CML: N-epsilon-carboxy methyl lysine; Lam-P1: Laminin P1; ADMA: asymmetric dimethylarginine.

2.2. Statistical Analyses

Because of their skewed distribution CML, laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA) were log-transformed. For continuous variables, paired and unpaired Student’s t-tests were used. Results are expressed as the mean ± SD (standard deviation) or as the median (range). To evaluate correlations, the Spearman’s correlation test was performed. Received operated curves (ROC) curves and the Chi-squared test for the area under the ROC curve (AUC) comparison was performed. All p values are based on a two-sided test of statistical significance. Significance was accepted at the level of p < 0.05. Statistical analyses were performed with the Stata statistical package.

3. Results

The main clinical and laboratory parameters of patients included in the study at baseline, according to treatment, are shown in Table 2.

Table 2. Baseline characteristics of type 2 diabetes mellitus patients included in the analysis of efficacy.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Brimonidine</th>
<th>Somatostatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 123</td>
<td>n = 97</td>
<td>n = 120</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.4 ± 7.1</td>
<td>63.7 ± 6.0</td>
<td>62.6 ± 6.6</td>
</tr>
<tr>
<td>Gender (% males)</td>
<td>66.1</td>
<td>66.0</td>
<td>65.0</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>30.8 ± 5.6</td>
<td>30.8 ± 5.3</td>
<td>31.1 ± 5.4</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>11.6 ± 5.8</td>
<td>11.1 ± 5.5</td>
<td>11.4 ± 5.5</td>
</tr>
<tr>
<td>Diabetes treatment (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diet</td>
<td>4.8</td>
<td>2.1</td>
<td>4.2</td>
</tr>
<tr>
<td>Oral agents</td>
<td>65.3</td>
<td>76.3</td>
<td>73.3</td>
</tr>
<tr>
<td>Oral agents + insulin</td>
<td>24.2</td>
<td>21.6</td>
<td>20.8</td>
</tr>
<tr>
<td>Insulin</td>
<td>5.6</td>
<td>0.0</td>
<td>1.7</td>
</tr>
<tr>
<td>HbA1C (%)</td>
<td>7.21 ± 0.97</td>
<td>7.22 ± 1.09</td>
<td>7.11 ± 0.92</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>71.0</td>
<td>73.2</td>
<td>71.7</td>
</tr>
<tr>
<td>Dyslipidemia (%)</td>
<td>69.4</td>
<td>67.0</td>
<td>67.5</td>
</tr>
<tr>
<td>Microalbuminuria (%)</td>
<td>19.3</td>
<td>22.7</td>
<td>19.1</td>
</tr>
<tr>
<td>Cardiovascular disease (%)</td>
<td>19.4</td>
<td>14.4</td>
<td>21.7</td>
</tr>
<tr>
<td>ETDRS 10/20-35(%)</td>
<td>42.7/57.3</td>
<td>38.1/61.9</td>
<td>43.3/56.7</td>
</tr>
<tr>
<td>BCVA letter score</td>
<td>85.9 ± 5.2</td>
<td>86.1 ± 5.2</td>
<td>85.7 ± 4.6</td>
</tr>
</tbody>
</table>

At baseline, the serum levels of CML and LamP-1 were not associated with age, gender, BMI, duration of diabetes, fasting plasma glucose, or hemoglobin A1c (HbA1c). A direct correlation was observed between ADMA and HbA1c ($r = 0.13; p = 0.016$); however, as occurred with CML and Lam-P1, we did not detect any relationship between ADMA and age, gender, BMI, or duration of diabetes. BMI: body mass index; ETDRS: Early Treatment Diabetic Retinopathy Study; BCVA: best corrected visual acuity.
3.1. Usefulness of Serum Biomarkers for Monitoring Neurodysfunction

The values of IT at baseline were directly correlated with baseline serum concentrations of CML \((r = 0.135, p = 0.013)\). Thus, serum levels of CML were significantly higher in subjects with elevated IT in comparison with those with an IT within the normal range, according to the normative database previously developed by the EUROCONDOR Consortium [33] (Figure 1). As mentioned above, we did not find any correlation between CML levels and HbA1c, which, in turn was unrelated to IT.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Comparison of baseline serum levels of N-epsilon-carboxy methyl lysine (CML; log-transformed) between patients with normal and abnormal implicit time (IT; IT ≥ 37.43 milliseconds). * \(p = 0.009\). AU: arbitrary units.

The increase in CML concentration throughout the follow-up was correlated to the worsening of IT in the placebo group \((r = 0.20; p = 0.03)\). However, this direct correlation was not observed in the groups treated with brimonidine or somatostatin. The AU of CML in predicting the increase in ≥2 SDs of IT in those patients treated with the placebo was 0.804 (95% CI: 0.585–1) (Figure 2).

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Prediction model of worsening of IT (increase of ≥2 SDs at the end of follow-up) based on the increase of serum CML levels during the first year of follow-up. AU: 0.804 (95% CI: 0.585–1). AU: arbitrary units.

We did not observe any relationship between either LamP-1 or ADMA and IT.

3.2. Usefulness of Serum Biomarkers to Monitoring Structural Changes

Baseline serum levels of CML correlated with macular retinal thickness (RT) \((r = 0.231; p < 0.001)\). In fact, diabetic patients with subclinical diabetic macular edema, as defined by The Diabetic Retinopathy Clinical Research Network (DRCR.net) [34], presented higher levels of CML than those with normal RT.
(CML log: \(2.42 \pm 0.22\) vs. \(2.32 \pm 0.28; p = 0.003\)). In addition, a correlation between CML and ganglion cell layer–inner plexiform layer (GCL-IPL) thickness was observed \((r = 0.156; p = 0.030,\) respectively).

A correlation between baseline Lam-P1 levels and GCL-IPL thickness was observed \((r = 0.114; p = 0.036)\). In addition, baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group \((r = 0.22; p = 0.016)\), but not in the groups treated with the neuroprotective drugs (brimonidine or somatostatin). Interestingly, a significant decrease in the serum Lam-P1 was observed in the group treated with somatostatin (SST) at 6 and 12 months. This effect was not seen in the placebo and brimonidine groups (Figure 3).

**Figure 3.** Evolution of Lam-P1 levels (log transformed) in the three therapeutic arms. Lam-P1 levels significantly decrease in type 2 diabetes mellitus patients treated with somatostatin. Lam-P1: laminin P1; BRIM: brimonidine; SST: somatostatin. *\(p < 0.001\) between Baseline and Month 6. \# \(p = 0.043\) between Month 6 and Month 12.

We did not find any relationship between the serum levels of ADMA and any of the structural parameters measured by SD-OCT.

### 3.3. Usefulness of Serum Biomarkers in Monitoring Early Microvascular Changes

We did not find any relationship between the severity of DR (ETDRS level) and the serum levels of the selected molecules (CML, Lam-P1, and ADMA) (Table 3). Their possible relationship to progression in the ETDRS scale could not be analyzed, because fewer than 10 patients increased by at least one step in ETDRS scale during the 2 years of follow-up.

**Table 3.** Baseline serum levels of biomarkers compared to severity of DR (ETDRS classification).

<table>
<thead>
<tr>
<th></th>
<th>ETDRS 10 (n = 140)</th>
<th>ETDRS 20-35 (n = 201)</th>
<th>(p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML (log-transformed)</td>
<td>2.35 ± 0.28</td>
<td>2.36 ± 0.26</td>
<td>n.s.</td>
</tr>
<tr>
<td>Lam-P1 (log-transformed)</td>
<td>2.46 ± 0.47</td>
<td>2.41 ± 0.47</td>
<td>n.s.</td>
</tr>
<tr>
<td>ADMA (log-transformed)</td>
<td>1.91 ± 0.27</td>
<td>1.90 ± 0.30</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

n.s. Not significant.
4. Discussion

This is the first study aimed at evaluating the usefulness of circulating biomarkers in the early stages of DR in a large and well-characterized cohort of patients with type 2 diabetes. We provide evidence that CML is a biomarker for both neurodysfunction and RT, whereas Lam-P1 may represent a biomarker for RT only. We did not find any relationship between the serum levels of ADMA and either neurodysfunction or structural changes in the retina.

Neurodysfunction is an early abnormality in the natural history of DR, detected even before the structural changes of the neurodegenerative process \[11,12\]. In the present study, we found a direct and significant correlation between baseline serum levels of CML and retinal neurodysfunction, assessed by the IT in patients with type 2 diabetes without DR or with only mild DR. In addition, the increase in CML concentrations throughout the study was related to impairment of IT in the placebo group, which represents the natural history of DR evolution, whereas such a relationship was no longer observed in the arms treated with neuroprotective drugs. This is an important finding, because both brimonidine and somatostatin have appeared able to ameliorate the increase of IT, thus preventing further worsening of neurodysfunction \[15\]. Hence, as CML ran in parallel to the IT throughout the study, it could be a useful marker for monitoring the effects of neuroprotective drugs, at least in terms of neurodysfunction.

Notably, no relationship between HbA1c and CML was observed, and this finding emphasizes the limited value of isolated values of HbA1c in capturing all the glycation process that occurs in diabetes.

CML, the most abundant among circulating AGEs, was elevated in the serum of patients with diabetes, and to an even greater extent in those with microvascular complications \[35–39\], including those patients with DR \[40\]. However, to the best of our knowledge, this is the first evidence that CML may be useful in detecting retinal neurodysfunction and predicting its worsening. In this regard, it should be noted that AGEs have been involved in the pathogenesis of neurodegenerative diseases like Alzheimer’s \[41,42\], whereas a relationship with retinal neurodysfunction has not been previously examined.

In this regard, our results suggest that CML and Lam-P1 could represent useful biomarkers to identify and monitor these different phenotypes. It should be noted that mfERG is a cumbersome and time-consuming procedure requiring specialized personnel, and is mainly reserved for clinical trials. The measurement of biomarkers would be simpler and
cheaper than mfERG. Therefore, in those patients in whom neurodysfunction has been identified, the assessment of the proposed biomarkers, particularly CML, could be useful in monitoring the natural history of the disease and the effect of treatment. In addition, this strategy could allow one to skip mfERG during follow-up or replace it with another, simpler examination, such as microperimetry. Furthermore, the measurements of biomarkers could give us complementary information about the impairment of the neurovascular unit. Nevertheless, although promising, our results should be validated in other cohorts.

It must be noted that serum concentrations of the biomarkers measured could be influenced by other microangiopathic complications, with particular reference to the kidney function. However, in the EUROCONDOR clinical trial, patients with renal failure (creatinine > 123.76 µmol/L) were excluded, and the results remain similar when adjusted by presence of microalbuminuria. The main limitation of our study is the low progression rate of microvascular disease, due to the short follow-up (2 years). This limiting factor precludes any conclusion being drawn on the usefulness of the selected biomarkers in terms of microvascular progression. Therefore, further clinical research with a longer follow-up is needed.

In conclusion, we found that CML and LamP1 could help us identify subjects with type 2 diabetes with the early stages of DR. The changes of these biomarkers could be a complementary tool for the assessment of neurodysfunction and retinal thickness in subjects with type 2 diabetes, and could also provide useful information when monitoring the effectiveness of treatments in the early stages of DR.

**Author Contributions:** Conceptualization, C.H. and R.S.; methodology, all authors; formal analysis, C.H. and R.S.; investigation, all authors; resources, all authors; writing—original draft preparation, C.H.; writing—review and editing, C.H. and R.S.; project administration, R.S.; funding acquisition, EUROCONDOR Consortium (coordinator: R.S.). All authors have read and agreed to the published version of the manuscript.

**Funding:** This project has received funding from the European Union’s Seventh Framework Programme for research, technological development, and demonstration, under grant agreement no. 278040.

**Conflicts of Interest:** Berta Ponsati is an employee of BCN Peptides, which holds the intellectual property related to the use of ocular somatostatin to treat diabetic retinopathy. No other potential conflicts of interest relevant to this article were reported.

**References**


